UBS Group
BRNS

UBS Group’s Barinthus Biotherapeutics BRNS Stock Holding History

UBS Group’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,152
Closed -$2.21K – 10524
2025
Q4 		$2.21K Buy
3,152
+3,139
+24,146% +$3.13K ﹤0.01% 9355
2025
Q3 		$16 Buy
+13
New +$16 ﹤0.01% 10158
2024
Q4 		– Sell
-1,432
Closed -$1.7K – 9950
2024
Q3 		$1.7K Sell
1,432
-85,221
-98% -$114K ﹤0.01% 8569
2024
Q2 		$121K Buy
86,653
+85,106
+5,501% +$192K ﹤0.01% 6039
2024
Q1 		$3.68K Hold
1,547
– – ﹤0.01% 7711
2023
Q4 		$5.71K Buy
1,547
+1,458
+1,638% +$4.92K ﹤0.01% 7767
2023
Q3 		$275 Sell
89
-904
-91% -$1.94K ﹤0.01% 8631
2023
Q2 		$2.05K Buy
+993
New +$2.35K ﹤0.01% 7815
2023
Q1 		– Sell
-3,751
Closed -$8.81K – 9634
2022
Q4 		$8.81K Sell
3,751
-1,437
-28% -$3.66K ﹤0.01% 8725
2022
Q3 		$17K Buy
5,188
+4,726
+1,023% +$20.1K ﹤0.01% 7585
2022
Q2 		$2K Sell
462
-1,494
-76% -$7.2K ﹤0.01% 9511
2022
Q1 		$10K Buy
1,956
+1,383
+241% +$11.1K ﹤0.01% 8396
2021
Q4 		$6K Buy
+573
New +$7.23K ﹤0.01% 9252

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group's BRNS Position: Q1 2026 in Review

UBS Group sold out of Barinthus Biotherapeutics (BRNS) in Q1 2026, closing a stake of 3,152 shares — an estimated $2.21K sold.

UBS Group first reported a position in BRNS in Q4 2021 and held it in 13 quarters. The position peaked at $121K in Q2 2024. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • UBS Group reported no remaining Barinthus Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 3,152 Barinthus Biotherapeutics shares in Q1 2026, an estimated $2.21K.
  • UBS Group first reported a position in Barinthus Biotherapeutics in Q4 2021 and held it in 13 quarters.
  • UBS Group's Barinthus Biotherapeutics position peaked at $121K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.